Bays F Barry's Form 4 filing
Treace Medical Concepts, Inc. (TMCI) · filed Nov 14, 2022
- Accession no.
- 0001209191-22-056467
- Filed
- Nov 14, 2022
- Trade date
- Nov 9-10, 2022
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions. Open-market sales total $581.4K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bays F BarryCIK 0001183554 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 9, 2022 | Common Stock | SSaleDisposed | −4,100 | $20.77F2 | −$85,157 | 1,559,837 | Direct | |
| Nov 9, 2022 | Common Stock | SSaleDisposed | −13,023 | $21.19F3 | −$275,957.37 | 1,546,814 | Direct | |
| Nov 10, 2022 | Common Stock | SSaleDisposed | −1,500 | $22.48F4 | −$33,720 | 1,545,314 | Direct | |
| Nov 10, 2022 | Common Stock | SSaleDisposed | −7,900 | $23.62F5 | −$186,598 | 1,537,414 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $20.0200 to $21.0150 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $21.0200 to $21.6000 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.1050 to $23.0100 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $23.1000 to $23.8950 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.